Entrada Therapeutics ($TRDA) Stock Hub: can higher doses turn delivery science into convincing clinical benefit?

01 Scenarios and the observations that would falsify them

Constructive. Higher exposure produces reproducible molecular improvement with tolerable repeat dosing; ENTR-601-45 adds consistent evidence; follow-up supports the functional pattern; VX-670 contributes a clinically interpretable signal. This could improve development confidence and funding options. Outlier-dependent responses or an inadequate safety margin would weaken the scenario.

Intermediate. Safety is manageable but biomarkers and function remain mixed, variable or too imprecise to design a pivotal trial. More cohorts and observation are required. Programs retain plausibility while time, spending and competition erode option value. Clearly reproducible dose-response evidence or a definitive setback would move the assessment away from this middle case.

Adverse. Useful exposure is difficult to reach safely, functional observations fail to reproduce, timing slips or competition sets a stronger standard. Funding becomes harder precisely when more work is needed. A coherent controlled dataset would challenge this case; positive press-release adjectives alone would not.

These are analytical pathways, not probability-weighted forecasts. Multiple datasets can reduce uncertainty, but shared chemistry means several apparent catalysts can still depend on the same underlying problem.

What Would Falsify This Reading

The reading here is that Entrada’s first Duchenne cohort left an exposure problem that higher doses may correct, and that cash covers the next tests but little beyond them. These observable developments would contradict it.

• Exposure that does not scale with dose. Cohort 2 at 12 mg/kg, guided to Q1 2027, showing exposure or dystrophin far below the company’s modeling.
• The same shortfall in exon 45. October ENTR-601-45 data at 5 mg/kg no better than exon 44 at 6 mg/kg would point to a platform-wide problem.
• A safety signal at higher doses. Serious adverse events, discontinuations or kidney-marker changes at 10 or 12 mg/kg.
• Function that fades in open-label follow-up. Year-end open-label data in which cohort 1’s Time to Rise velocity gains are not maintained.
• Financing or slippage before the data. A large raise or heavy ATM use before the Q1 2027 readout, or cohort 2 data slipping past that quarter.

These are tests of the reading, not predictions. None of them had occurred as of October 2, 2026.

02 Company history, leadership and governance

Entrada was incorporated in September 2016 as CycloPorters and adopted its current name in October 2017. Its public-market chapter began with the October 2021 IPO. It remains a development organization: clinical execution and financing discipline are more relevant in 2026 than commercial sales execution. IPO prospectus · 2026 proxy

Dipal Doshi has led the company since 2017 and previously served as chief business officer at Amicus. Executives include Natarajan Sethuraman, president of R&D; Nathan Dowden, president and chief operating officer; and CFO Kory Wentworth. Kush Parmar chairs the board separately from the CEO. Other directors include Peter Kim, Mary Thistle, Bernhardt Zeiher, Maha Radhakrishnan and Gina Chapman. Leadership biographies · Board and committees

Scientific, operating and investment experience can aid capital allocation, but it does not replace accountability. The classified board described in the proxy means shareholders do not elect all directors annually. The practical governance question is whether management updates dose selection, spending and priorities promptly when evidence changes. Venture representation can provide continuity while still requiring scrutiny of compensation and related-party disclosures.

At the June 10, 2026 annual meeting, stockholders re-elected Peter Kim and Bernhardt Zeiher as Class II directors until 2029, each with more than 22 million votes for and about 2 million withheld. Of 38,820,616 shares entitled to vote, 33,190,234 were represented. The equity-plan amendments described in the dilution chapter passed by a much narrower margin. June 10, 2026 Form 8-K

03 What EEV delivery is trying to solve

Large therapeutic molecules can enter a cell yet remain trapped in compartments called endosomes. Entrada’s Endosomal Escape Vehicle, or EEV, uses a cyclic cell-penetrating peptide attached to therapeutic cargo to improve intracellular delivery and release. More useful drug reaching its target is the intended advantage. These are company-described design goals whose clinical value must be demonstrated. EEV platform description

In DMD, the cargo is a phosphorodiamidate morpholino oligomer, or PMO. Exon skipping aims to restore the RNA reading frame so cells produce a shorter dystrophin protein. Eligibility depends on mutation: an exon 44 candidate does not treat every person with Duchenne. This is repeat-dose treatment, not one-time gene replacement. Clinical-study overview

Delivery, target engagement and patient benefit are distinct hurdles. Exposure and exon skipping can support the mechanism; dystrophin moves closer to the disease biology; sustained function is what matters to patients. Success at one level does not establish the next. Claims about muscle stem-cell access and regenerative potential remain preclinical hypotheses, not established benefits in treated children.

Population size explains the multi-exon strategy. On May 7, 2026 the company estimated about 41,000 people with Duchenne in the U.S. and Europe, roughly 14,000 amenable to skipping exon 44, 45, 50 or 51, and exon 44 at about 8% of patients globally; the August 10-Q cites a lower figure, over 11,500 amenable patients. Either way, each exon is a rare subset of a rare disease. May 7 release · Q2 2026 Form 10-Q

04 Pipeline map and economic ownership

Company pipeline · August update. Development stages are not approval probabilities. Discovery programs do not have established human efficacy.

The portfolio offers several experiments, but many share delivery chemistry, manufacturing requirements or biological assumptions. VX-670 has different disease biology and retained economics. A sound valuation does not treat everything as one binary bet or assign each listed asset an independent, fully funded commercial value.

05 ENTR-601-44: what the first cohort did and did not show

ELEVATE-44-201 started with eight ambulatory participants randomized 3:1 to treatment or placebo. Cohort 1 used 6 mg/kg intravenously every six weeks for three doses, with biopsy assessment at day 127. Actual ages were 6–17 within a 4–20 eligibility range. All eight entered open-label follow-up. May cohort report · August study slides

The reported dystrophin increase was 2.36 percentage points above a 4.00% baseline; exon skipping rose 2.31 points above 2.66%. These are absolute changes, not a 2.36-fold increase. There were no reported serious adverse events or adverse-event discontinuations, and described kidney markers remained normal. Pediatric exposure was below model predictions. A time-to-rise velocity finding reached p<0.05 in a post hoc analysis. Reported results

The February 2026 annual report had anticipated double-digit dystrophin in this first cohort; the reported result did not meet that earlier expectation. 2025 Form 10-K, filed February 26. Further dose investigation is justified, but this is not reliable proof of functional efficacy. Baseline dystrophin, patient heterogeneity, measurement variability and the tiny placebo group make superficial comparisons with other companies’ percentages misleading.

Cohort 2 increases dosing to 12 mg/kg, with results guided to Q1 2027; on October 14, 2026 the independent data monitoring committee recommended starting cohort 3 at 18 mg/kg. The question is whether greater exposure improves biological activity without narrowing the safety margin. Follow-up adds duration and repeat-dose information, but without a concurrent blinded comparator it cannot establish causality. A higher average driven by an outlier would be less persuasive than a coherent response across patients. Dose-escalation plan · Current timing

The May 7, 2026 release adds context. Treated participants averaged 9.3 years of age, all on stable steroids, with baseline dystrophin lower than in competing exon 44 studies. Normal kidney markers matter because, as the company notes in its 10-Q, the kidney has historically been the organ of toxicity concern for PMO-based oligonucleotides and peptide conjugates. May 7 release, SEC exhibit

On function, the May release reported a mean change in Time to Rise velocity versus placebo of 0.115 and a mean change of 0.08 in the treated group, and described the result as 3.5 times the minimal clinically important difference of 0.023. The test was a post hoc analysis with p<0.05. With six treated boys and two on placebo, one participant’s trajectory can move a group mean substantially, and the reported correlation between dystrophin and TTR velocity is hypothesis-generating, not a threshold for benefit.

The 10-Q filed on August 5, 2026 reports a lower figure for the same post hoc comparison. It reports a statistically significant improvement versus placebo of 2.40 seconds in Time to Rise and of 0.09 rises per second in TTR velocity, both post hoc, and positive trends in the 10-meter walk/run. The August 2026 company presentation also uses 0.09. The filings do not explain the difference between the two figures, so comparisons with other programs depend on which one is used. The 10-Q puts total mean dystrophin at 6.36% and cites complex multi-exon deletions among possible reasons for the modest biomarker response. Q2 2026 Form 10-Q

Pediatric exposure matched juvenile, not adult, non-human primate data, and the company’s updated modeling predicts significantly higher AUC and dystrophin at 12 mg/kg. The timetable moved too: cohort 2 data guided by year-end 2026 on May 7 were placed in the first quarter of 2027 on August 5. Pharmacokinetic disclosure · August 5 timing

ClinicalTrials.gov lists ELEVATE-44 as NCT07037862, a quadruple-masked, placebo-controlled study in which Part B tests the dose chosen in Part A; as listed on October 2, 2026, it shows 24 estimated participants, 14 European sites and estimated primary completion on March 28, 2029. The 10-Q says Entrada intends to open an expansion cohort because the study is designed to support a U.S. accelerated approval; in December 2025 the FDA granted ENTR-601-44 Rare Pediatric Disease Designation. Neither is an FDA agreement on endpoints. NCT07037862

06 ENTR-601-45: a second human test

ELEVATE-45-201 studies ambulatory patients with exon 45-skipping amenable DMD. The phase 1/2 design plans 24 participants across three eight-person cohorts, randomized 3:1, with three intravenous doses six weeks apart before open-label treatment. Dose levels are 5 mg/kg, 10 mg/kg and potentially 15 mg/kg. Study and monitoring update

In June, the independent monitoring committee reviewed safety and pharmacokinetic information from the first eight participants and allowed escalation to 10 mg/kg. That is a development milestone, not a public efficacy demonstration. October is the next opportunity to examine patient results. Escalation decision · October guidance

A constructive result would connect tolerable dosing with adequate exposure and a credible molecular response. Weak findings would raise questions about whether ENTR-601-44’s challenges extend across the DMD platform. Neither outcome follows automatically, because cargo and populations differ. Functional observations remain exploratory until supported by appropriate size, duration and statistical design. Cohort 2 is guided to H1 2027 and cannot automatically be placed before March 31.

ClinicalTrials.gov lists ELEVATE-45 as NCT07038824, with the same design, 24 estimated participants, 15 European sites and estimated primary completion on March 1, 2029, as listed on October 2, 2026. On August 5 the company said all cohort 1 participants had moved to open-label dosing, cohort 2 at 10 mg/kg was dosing, and a third cohort at up to 15 mg/kg would follow only if needed. In the 10-Q management says it expects ENTR-601-45 to be best in class, an expectation rather than a result. NCT07038824 · August 5 update

Three things deserve attention in the October dataset. First, whether 5 mg/kg in exon 45 shows the same pediatric exposure shortfall seen at 6 mg/kg in exon 44. Second, baseline and absolute dystrophin change on the same basis as ELEVATE-44. Third, the benchmark: exon 45 already has an approved PMO, Sarepta’s casimersen, whose confirmatory ESSENCE study missed its primary endpoint and was presented again, with post hoc analyses, as a poster at the World Muscle Society congress on September 30, 2026. Sarepta WMS 2026 presentations

07 VX-670 and the Vertex relationship

VX-670, formerly ENTR-701, is designed to address pathogenic CUG-repeat RNA in DM1 while preserving DMPK, unlike approaches that reduce DMPK RNA. GALILEO’s multiple-ascending-dose portion assesses safety, muscle-biopsy splicing correction and function, including video hand-opening time and quantitative muscle testing. Vertex expects data in H2 2026; no exact day is verified. Vertex Q2 update · DM1 overview

The December 2022 collaboration included $224 million upfront and $26 million in equity, paid at the 2023 closing, plus up to $485 million of contingent milestones and tiered royalties. Vertex handles global development, manufacturing and commercialization. Historical payments are not incoming catalyst cash; the milestone ceiling is not a receivable. Agreement economics · Closing confirmation

The readout has two implications: retained economic participation and evidence about delivery. Treating them as two independent sources of value would overstate what the readout means. A successful medicine would not give Entrada all product revenue, while favorable delivery evidence still needs validation in each DMD candidate. The strongest result would align molecular correction with interpretable function rather than substitute the first for the second.

The sponsor’s trial page lists 47 participants for the overall GALILEO study and eligibility ages 18–64. This is not a claim that all 47 belong to the pending multiple-dose analysis. Exact dose-level allocation and numerical patient safety results are not established by the cited operating update and are left unspecified. Vertex trial page · NCT06185764 registry

As listed on October 2, 2026, GALILEO (NCT06185764) is active, not recruiting, with 47 participants enrolled and estimated primary completion on February 2, 2027; Vertex had not reported VX-670 data by that date. NCT06185764

The DM1 benchmark moved just before that readout. On September 29, 2026, Dyne reported one-year ACHIEVE data for z-basivarsen, which also aims to correct DM1 splicing, by a different mechanism. In a pooled group of 25 to 26 participants, video hand opening time fell 3.2 seconds from an 8.2-second baseline at six months, against a 0.4-second rise in 14 placebo participants; only 8 of 26 received the registrational dose for the full year. Dyne expects registrational-cohort topline data in the first quarter of 2027 and a potential accelerated-approval submission in the third quarter. Dyne, September 29, 2026, SEC exhibit

08 Earlier programs: options on future development

ENTR-601-50 has UK authorization for a phase 1/2 trial; additional regulatory steps and timing are being evaluated against lead-program data. ENTR-601-51 has completed CTA-enabling studies, with filings similarly sequenced after review of ongoing work. Neither has a confirmed patient readout in the next six months. Development update · Current pipeline

ENTR-801 targets USH2A exon 13 in inherited retinal disease. Proposed durability and intravitreal use remain preclinical development hypotheses. The anticipated nomination of another ocular candidate is a discovery milestone, not a clinical binary. Ocular presentation

These projects may become valuable if Entrada establishes transferable delivery capabilities. They also compete for finite money and attention. Delaying an asset until the lead programs clarify exposure and safety could reflect rational prioritization rather than scientific failure, although it reduces near-term announcements. An authorized trial, an initiated trial, a dosed patient and a clinical result are different stages.

A long-term extension protocol, ENTR-DMD-202, was accepted by U.K. and European authorities. ClinicalTrials.gov lists it as ELEVATE-LTE (NCT07682129), an open-label phase 2 study for an estimated 80 participants, shown as not yet recruiting as listed on October 2, 2026, with estimated primary completion in March 2032. In the U.S., Entrada plans to re-engage with the FDA to discuss a higher starting dose for the adult ELEVATE-44-102 study; no design or timing has been announced. August 5 update · NCT07682129

On the ocular side, Entrada plans to announce a second clinical candidate in inherited retinal disease in the second half of 2026; as of October 2, 2026 it had not done so. A candidate announcement would add an option, not patient data; ocular programs cost $0.6 million of direct research spending in the second quarter, small but rising. Q2 2026 Form 10-Q

09 Catalyst calendar through March 2027

Entrada guidance · Vertex guidance. These are reporting windows, not release dates. October and Q1 are distinct; the H2 and late-year events could cluster. As of October 2, 2026, none of the clinical readouts in this table had been released.

Guidance has already evolved. A conference appearance is not automatically new efficacy data, and “first half 2027” does not mean “first quarter.” Merlintrader has found no public announcement of an Entrada FDA action date. Recheck management’s latest communication before treating an event as imminent: slippage changes both the information available and the funding needed to reach the next milestone.

Competitor dates frame each of those windows.

Dyne BLA acceptance, July 20, 2026 · Dyne DM1 update, September 29, 2026. Dates as published by each company.

10 Cash, spending and operating runway

Financial statements · Earnings release. Management expects funding into Q3 2027. No material funded borrowing is shown; operating-lease liabilities are $48.544 million.

R&D accounts for approximately 77% of the two major expense categories. Collaboration revenue is not recurring product sales and should not be projected as a stable commercial franchise. Historical first-half operating cash use annualizes to $148.3 million, but trial cadence, manufacturing, working capital and partner payments can change burn.

Practical financing runway ends before cash reaches zero: management needs time and negotiating flexibility. Cash supports experiments; it does not automatically fund all future pivotal development.

Against Q2 2025, R&D fell from $37.877 million and G&A from $10.922 million, while interest and other income dropped to $2.235 million from $3.924 million as cash shrank. The Q2 net loss was $1.01 per share on 42,221,665 weighted-average shares, against $1.04 a year earlier. The wider first-half loss, $82.480 million against $60.452 million, comes from lower collaboration revenue after the VX-670 research plan was substantially completed in early 2025, not from higher spending. Q2 release, SEC exhibit

The 10-Q breaks research spending down by program, which shows where the money is going.

Q2 2026 Form 10-Q, research and development by program. Direct DMD spending was about $16.7 million, against $17.3 million of unallocated personnel and facility costs; the exon 50 and 51 lines fell, consistent with sequencing them behind the lead readouts.

At June 30, 2026, total liabilities were $65.466 million and the accumulated deficit $355.6 million. June cash and securities equal about $5.27 per economic share, counting the 3.367 million pre-funded warrants, against the October 1, 2026 close of $5.68; the dates differ and cash has been spent since June, so the comparison is orientation, not a valuation floor. Balance sheet and liquidity

Runway arithmetic, as a Merlintrader calculation: first-half operating cash use of $74.158 million averages about $37.1 million per quarter. At that pace, $223.0 million would last roughly six quarters from June 30, close to the end of 2027. Management’s narrower guidance, into the third quarter of 2027, implies rising spending; that is an inference, not a published budget. Only one to two quarters separate the last guided readout, ELEVATE-45 cohort 2 in the first half of 2027, from the guided end of runway, so financing is likely to be on the 2027 agenda whatever the data show.

11 Shares, pre-funded warrants and dilution

Ordinary shares were 38,936,669 at July 31, 2026. June reporting includes 3,367,000 pre-funded warrants with a nominal $0.0001 exercise price, giving approximately 42.304 million basic economic shares. Potential awards comprise 6.768 million options, 2.880 million RSUs and 0.215 million PSUs. They are not all issued or immediately dilutive on the same basis. Capital-stock and award notes

A $150 million ATM agreement provides a financing mechanism; no shares were sold through it in Q2. Authorized shares, weighted-average EPS shares and outstanding shares are distinct. Choosing whichever denominator makes the stock look cheapest is unreliable.

Almost all the purchase price of pre-funded warrants has already been paid, so excluding them overstates the economic claim of an ordinary share. Options and awards require separate treatment for exercise price and vesting. September inducements also show why June’s award inventory is not a fixed ceiling. New award disclosure

Financing after good data can support progress on better terms, but still increases the denominator. The relevant question is how much capital the next plan requires per unit of uncertainty resolved, rather than simply whether shares remain below an arbitrary threshold.

Governance changes also touch dilution. At the June 10, 2026 annual meeting, stockholders approved amendments to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan so that outstanding pre-funded warrants are added to the share base used each December 31 to calculate the evergreen annual increase. The practical effect is a larger automatic reserve for equity awards at each future year-end calculation. It was the closest vote of the meeting: 14,686,713 for and 9,566,186 against on the incentive plan, close to 40% of votes cast opposed. June 10, 2026 Form 8-K

12 Institutional holders and insider transactions

Baker primary filing · MPM primary filing · CEO Form 4. Other filings: COO Form 4 · R&D president Form 4 · CFO Form 4 · MPM Form 4, August 24-26 · MPM Form 4, September 4-9 · MPM trade details, Exhibit 99.2.

A 13F common-stock position differs from beneficial ownership including exercisable instruments. Affiliated MPM reporting persons are not separate holders. These are snapshots, not proof of current positions.

MPM disclosed actual open-market reductions, but not the investment motive. The CEO sale covered mandatory taxes; calling it discretionary bearish selling would mislead. Institutional participation may aid liquidity and diligence without predicting outcomes or obliging a fund to remain invested. Third-party market data as of October 2, 2026 put institutional ownership near 53.5% and insider ownership near 38.6%; these are third-party estimates, not audited figures.

The MPM sequence is the most concrete ownership change of the quarter. The trade details attached to the September 10 amendment list open-market sales on every trading day from August 24 to September 9, 2026, at daily weighted-average prices between $6.99 and $7.54, the largest 192,500 shares on September 8. The holding fell from 4,381,062 to 3,885,115 shares, about 11%, taking the stake just below 10%. The September 2 executive Form 4s are different in kind: all carry code F and state that the shares were sold automatically to cover taxes on vesting awards.

13 Competition: the evidence bar is moving

Novartis’s del-zota is a direct, more advanced exon 44 competitor: its accelerated-approval submission was reported in Q2 and priority review confirmed in September. Entrada needs a worthwhile clinical and treatment profile, not simply another exon-skipping molecule. Novartis Q2 update · September update

Sarepta’s casimersen is already marketed for exon 45. Sarepta’s applications seeking traditional-approval conversion for AMONDYS 45 and VYONDYS 53 have a February 28, 2027 FDA target date. ESSENCE missed its primary endpoint, despite numerical trends favoring treatment and subsequent post hoc analyses. The FDA decision is a competitor event, not a TRDA PDUFA, and may inform the broader evidentiary discussion. FDA-acceptance announcement

Novartis’s DM1 HARBOR trial missed its primary video hand-opening endpoint in September. Secondary and exploratory activity did not rescue that result. VX-670 differs mechanistically: importing the same outcome would be unjustified, but ignoring the warning about functional validation would be equally weak analysis. HARBOR disclosure

Compare assays, baseline dystrophin, age, disease stage, background care, biopsy timing and duration before drawing conclusions from separate studies. A headline percentage cannot establish superiority. Six-week dosing is attractive only if efficacy and safety persist across the interval.

Exon 51, the largest exon-skipping population and the target of Entrada’s ENTR-601-51, is also moving. On July 20, 2026, Dyne Therapeutics announced FDA acceptance, with priority review, of its BLA for z-rostudirsen in exon 51 Duchenne under the accelerated approval pathway, based on dystrophin as a surrogate endpoint, with a PDUFA target action date of January 21, 2027; Dyne doses once every four weeks. If approved, it would set the exon 51 bar before ENTR-601-51 enters the clinic. Dyne BLA acceptance

Gene therapy is the other benchmark. On September 30, 2026, Sarepta presented at the World Muscle Society congress two-year ELEVIDYS data in 25 ambulatory patients treated at ages 8 to 12, compared with 99 matched external-control patients from natural-history datasets, reporting benefits on the North Star Ambulatory Assessment, time to rise from the floor and the 10-meter walk/run, and no new safety signals. External controls are not randomized evidence, but they show the functional language the field now expects. Sarepta WMS 2026 data

14 Regulatory pathway and intellectual-property limits

The original U.S. ENTR-601-44 hold was lifted in February 2025. The separate adult ELEVATE-44-102 program remains subject to dose and design discussions; it is not the current global ambulatory study. Authorization permits investigation, not commercial approval. Hold-resolution filing · Adult-study update

The latest 10-Q describes licensed IP, including Ohio State-related rights, and states that Entrada has no issued patents covering its oligonucleotide therapeutic candidates. This does not mean the platform has no IP. Pending claims, licensed technology, know-how and regulatory exclusivity have different scopes and durations. Merlintrader does not assign a blanket expiry date or a freedom-to-operate conclusion. IP risk disclosures

Scientific differentiation and enforceable commercial protection are separate questions. Good clinical data would leave manufacturing, regulatory, reimbursement and competitive issues. Accelerated approval is a possible route, not an FDA commitment to accept a particular biomarker dataset. Management’s development ambition is not a regulatory outcome.

The FDA’s July 2026 acceptance of Dyne’s exon 51 filing, based on dystrophin as a surrogate, shows the agency still reviews dystrophin-based applications; it does not say what level would suffice. Entrada’s stated path, an expanded ELEVATE-44 study designed to support accelerated approval, depends on dystrophin the first cohort did not show.

15 A valuation framework, not a target price

The $5.68 October 1, 2026 close multiplied by July ordinary shares gives $221.16 million of equity value. Including pre-funded warrants gives $240.28 million. Subtracting June cash and securities produces approximately $17.28 million before leases, or $65.82 million after adding lease liabilities. Historical price · Balance-sheet and share inputs

This mixed-date bridge is not live enterprise value: the cash predates the price by three months and excludes subsequent spending. It is not liquidation analysis. Cash committed to development is consumed, leases remain obligations, and winding down costs money. Apparent proximity to cash does not create a trading floor.

A future model should separate owned DMD value from Vertex milestones and royalties, then deduct development costs and corporate expenses while allowing for financing. Eligible patients, uptake, pricing, competition, approval timing and probabilities must be explicit. Current data do not justify false precision. The useful exercise is sensitivity: identify which upcoming observations would change those assumptions, and in which direction. A low enterprise-value calculation is a starting point for those questions, not their answer.

Analyst coverage: third-party market data as of October 2, 2026 showed a mean analyst target of $17.00 and a consensus leaning to buy-equivalent ratings. Merlintrader has not been able to verify the underlying dated brokerage notes, so no target-price table is shown here, and aggregated consensus figures are not a measure of fair value.

16 Short interest, liquidity and sentiment

Nasdaq reported short interest of 2,744,145 shares at the September 15, 2026 settlement, against average daily volume of 340,415 shares, or 8.06 days to cover. That equals about 7.0% of the 38,936,669 ordinary shares outstanding at July 31; third-party float estimates as of October 2, 2026, which exclude affiliated holders, are much smaller, near 24 million shares, which would put the ratio near 11.5%. Nasdaq short-interest series

The trend matters more than the single print. Short interest was 852,247 shares at the April 15, 2026 settlement, rose to 1,507,737 by May 15, after the first ELEVATE-44 data, to 2,111,685 by June 30, 2,345,803 by August 31 and 2,744,145 by September 15. The position more than tripled in five months ahead of the October and Q1 2027 readouts; that reflects positioning on outcome and financing, not a forecast.

This is meaningful positioning, not proof of an extreme squeeze. Days to cover can look high because ordinary volume is low; it does not mean every short must buy within that period. A favorable catalyst can attract demand and covering, while unfavorable data can overwhelm a small float with selling.

No verified aggregate Stocktwits bullish/bearish percentage is asserted. A live feed may show current discussion, but selected messages are not a representative investor survey. The useful questions are whether expectations have changed, liquidity can accommodate a position and discussion matches the trial design. Social enthusiasm and the short ratio cannot establish the probability or direction of a clinical surprise.

17 What would change the investment debate

Entrada’s next six months are unusually informative for a company of this size. The strongest reason to follow TRDA is the opportunity to see initial human activity become a repeatable clinical profile across doses and programs. The strongest caution is that the first dataset has not yet demonstrated that progression.

The October 14 exon 45 readout and Q1’s higher-dose exon 44 results occupy distinct windows, with DM1 and follow-up adding context. A useful update should strengthen the chain from exposure to molecular correction to patient function, while preserving safety and a credible funding plan. If that chain stays weak, the number of announcements and historical cash should not distract from it. This is a research framework, not a buy/sell instruction or promised return.

As of October 2, 2026, the checklist is short: exon 45 exposure and absolute dystrophin against exon 44, kidney markers and prespecified function; whether VX-670 data include hand opening time; and the third-quarter report, which in 2025 came on November 6, for cash, ATM use and runway.

18 Sources and research method

Data as of October 2, 2026. Financial statements are primarily June 30; price is the October 1, 2026 close; ownership and short-interest dates accompany the figures. Management expectations are not independently established outcomes. A release and its SEC reproduction verify transcription, not independent clinical replication.

Clinical evidence and timing

• May 7, 2026: initial ELEVATE-44 data
• June 2, 2026: ELEVATE-45 escalation
• August 5, 2026: Entrada Q2 and guidance
• August 2026: clinical presentation
• August 3, 2026: Vertex and GALILEO

Company, finance and ownership

• June 30 Form 10-Q
• May 7 Q1 release
• April 24 proxy
• Baker June 30 13F
• MPM September 10 13D/A
• September 3 CEO Form 4

Partnership and competition

• Original Vertex agreement
• September 8 Novartis update
• June 30 Sarepta FDA acceptance

Registries, filings and competitor updates added October 2, 2026

• ClinicalTrials.gov NCT07037862 (ELEVATE-44)
• ClinicalTrials.gov NCT07038824 (ELEVATE-45)
• ClinicalTrials.gov NCT07682129 (ELEVATE-LTE)
• ClinicalTrials.gov NCT06185764 (GALILEO)
• May 7, 2026 ELEVATE-44 release, SEC exhibit
• August 5, 2026 Q2 release, SEC exhibit
• June 10, 2026 annual-meeting Form 8-K
• MPM trade details, September 10, 2026
• MPM Form 4, September 9, 2026
• Dyne BLA acceptance, July 20, 2026
• Dyne DM1 data, September 29, 2026, SEC exhibit
• Sarepta WMS 2026 data, September 30, 2026
• Sarepta WMS 2026 presentation list, September 25, 2026

Market data

• Nasdaq historical prices
• Nasdaq short interest

Calculations and scenarios are Merlintrader analysis. No unpublished results, release days, social-sentiment percentages, target prices or success probabilities have been invented. Current guidance supersedes earlier timing.